Licarbazepine

DRUG8 trials

Sponsors

Novartis Pharmaceuticals, Novartis

Conditions

Bipolar DisorderBipolar I DisorderHealthy

Phase 1

Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine

CompletedNCT00424671

NovartisHealthy

Start: 2006-11-30Target: 16Updated: 2007-06-22

Effect of Severe Renal Impairment on Pharmacokinetics and Metabolism of a Single Administration of Licarbazepine

CompletedNCT00426036

NovartisHealthy

Start: 2006-06-30Target: 12Updated: 2007-06-22

Phase 3

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

CompletedNCT00099229

Novartis PharmaceuticalsBipolar Disorder

Start: 2004-11-30End: 2006-08-31Updated: 2017-02-23

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

CompletedNCT00107926

Novartis PharmaceuticalsBipolar Disorder

Start: 2004-10-31End: 2007-08-31Updated: 2017-03-22

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

CompletedNCT00107939

Novartis PharmaceuticalsBipolar Disorder

Start: 2004-11-30End: 2007-04-30Updated: 2017-03-22

An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.

CompletedNCT00228059

NovartisBipolar I Disorder

Start: 2005-01-31End: 2007-07-31Updated: 2017-02-23

An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder

CompletedNCT00238485

NovartisBipolar I Disorder

Start: 2005-01-31End: 2007-07-31Updated: 2017-03-28

Phase 4

Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder

CompletedNCT00139594

NovartisBipolar Disorder

Start: 2004-12-31End: 2007-07-31Updated: 2017-03-28